Oncotelic has two pharmacological agents in clinical trials to manage Covid-19, the disease caused by the SARS-CoV-2 virus. OT-101 and ARTIVeda both work by inhibiting TGF-β to neutralize the SARS-CoV-2 virus.
Upon assessing the broad impact of the SARS-CoV-2 virus and associated COVID-19 complications, the company tested OT-101 and Artemisinin, both of which showed potent activity in the lab and promising data for treating the virus infection and associated complications based on the their mechanism of action.
Study Title | Intervention | Control | Status |
---|---|---|---|
A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study of OT 101 in Hospitalized COVID-19 Subjects: C001 2020 01 | OT-101 | Standard of Care | Recruiting |
A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19: ARTI/WBPL/P4/2020/01 | ArtiVeda | Standard of Care | Recruiting |
A Double Blind, Randomized, Placebo Controlled, Multi Center Study of OT 101 in Hospitalized COVID 19 Subjects: C002-2020-01 | OT-101+ARTIVeda | Standard of Care+ARTIVeda | Not yet recruiting |
A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19: ARTI/OT/P2/2020/01 | ARTIVeda | Standard of Care | Not yet recruiting |
ARTIVeda
TGF-β inhibitor to address the COVID-19 pandemic in India. A similar product, ArtiShield, will be available outside of India.
OT-101
OT-101 has a similar mechanism of action as ARTIVeda, and is currently in phase 2 testing.